利凡诺联合米非司酮和米索前列醇用于孕中期引产的疗效观察

Clinical Effect of Rivanol Combined with Mifepristone and Misoprostol on Mid-trimester Odinopoeia

目的探讨利凡诺联合米非司酮和米索前列醇用于中孕(孕13~27周)引产的临床疗效。方法选取2013年9月至2017年3月在湖北省妇幼保健院妇产科自愿要求终止妊娠孕中期患者88例,将其随机分为观察组及常规组,观察组患者给予利凡诺联合米非司酮和米索前列醇,常规组患者给予米非司酮和米索前列醇,比较其引产情况及安全性指标。结果观察组及常规组患者引产成功率分别为97.77%及95.45%,差异无显著意义(P>0.05),而观察组患者清宫率为11.36%,显著低于常规组的36.36%(P<0.05),且观察组患者用药至宫缩时间、引产时长、产后2h出血量、出血天数、胎盘残留率均显著低于常规组(P<0.05),同时,观察组患者治疗后腹痛情况及不良反应发生情况均显著低于常规组。结论采用利凡诺联合米非司酮和米索前列醇对患者进行引产,用药至宫缩时间和产程短,术后阴道出血量少,对患者治疗疼痛程度及不良反应发生情况控制程度较好,适用于中孕引产,值得临床推广。

Objective To investigate the clinical efficacy and safety of rivanol combined with mifepristone and misoprostol for induction of labor during pregnancy（13 weeks to 27 weeks of pregnancy）.Methods Between September 2013 and March 2017,88 patients of gestational age who voluntarily requested to terminate their second trimester of pregnancy in our hospital were selected.They were randomly divided into the study group and conventional group.Patients in the study group were treated with rivanol combined with mifepristone and misoprostol,while the conventional group was given mifepristone and misoprostol.Labor induction and safety indicators were compared between the two groups.Results The success rate of induction of labor in the study group and the conventional group was 97.77% and 95.45%,respectively.There was no significant difference（P 〉0.05）.The rate of clearing in the study group was 11.36%,which was significantly lower than that in the conventional group（36.36%）（P〈 0.05）.The contraction time,length of induction of labor,2 hpostpartum hemorrhage,days of bleeding,placental residual rate were significantly shorter or lower in the study group than in the conventional group（P〈 0.05）.The incidence of abdominal pain and adverse reactions in the study group was significantly lower than that of the conventional group after treatment.Conclusion The use of rivanol combined with mifepristone and misoprostol for induction of labor in patients can lead to a high rate of induction of labor,a short interval between medication and contraction,a short duration of labor,less postoperative vaginal bleeding,and better control of pain and adverse reactions.It is applicable to mid-pregnancy odinopoeia,which is worthy of clinical promotion.